Nine patients in three cohorts are planned to receive escalating doses of 2, 5, or 10 million autologous, adipose-derived stem cells via intraventricular injection. Participants must be younger than ...

The global autologous wound care market is set to experience significant growth, with its valuation expected to reach USD ...

More information: Lindsay Zhou et al, Feasibility and safety of autologous cord blood derived cell administration in extremely preterm infants: a single-centre, open-label, single-arm, phase I ...

(IN BRIEF) AstraZeneca’s Calquence (acalabrutinib) has been approved by the U.S. FDA for the first-line treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ...